Agios Pharmaceuticals, Inc. (AGIO)

Agios Pharmaceuticals, Inc. (AGIO) is a healthcare company (biotechnology) based in the United States. The share price is $29.32, down 2.75% on the day, which values the company at $1.75B. Price as of 17 Nov 2026, 17:29 UTC, from Yahoo Finance.

Key facts

Share price
$29.32−2.75% today
Market value
$1.75B
Funk Score
61/100
Against its own history
Below its usual priceusual price $37.26
200-week average
$32.409% below
Sector
Healthcare

Figures as of . Prices from Yahoo Finance (may be delayed); statements from company filings with the SEC and Yahoo Finance. Estimates, not advice.

Agios Pharmaceuticals, Inc. in more detail

AGIO trades at -9.2× next year's expected earnings, 12.5× sales. Measured against its own history, the price is 21% below what its usual multiples would imply ($37.26) — below its usual price. It sits 9% below its 200-week average of $32.40.

Its Funk Score is 61 out of 100 (financial strength 8.1, profitability 2.4, growth 10.0, value 4.0, each out of 10).

In its favour: Altman Z in the safe zone; Operating margin is expanding. Worth checking: Beneish M-score flags the accounts; Share count keeps rising.

1 of the superinvestors tracked here hold AGIO, including Andrew Spokes (1.0% of the portfolio).

Superinvestors holding AGIO

1 of the investors tracked here report a position in their latest 13F filing.

Agios Pharmaceuticals, Inc. (AGIO): questions and answers

What is Agios Pharmaceuticals, Inc.'s market cap?

Agios Pharmaceuticals, Inc. is valued at $1.75B at a share price of $29.32.

Is AGIO overvalued or undervalued?

Against its own history, AGIO is below its usual price: the price is 21% below the $37.26 implied by the median multiples it has traded at (price / sales, price / book). That compares the stock with its past; it does not say whether the business now deserves a higher or lower multiple.

Is AGIO above its 200-week moving average?

No. AGIO is 9.5% below its 200-week average of $32.40. Long-term investors watch that line because strong companies rarely trade below it for long.

How fast is Agios Pharmaceuticals, Inc. growing?

Over the last three fiscal years Agios Pharmaceuticals, Inc.'s revenue grew 56.0% a year; over ten years revenue grew -0.9% a year.

Does AGIO pay a dividend?

Agios Pharmaceuticals, Inc. does not currently pay a regular dividend.

Which famous investors own AGIO?

In their latest quarterly filings, Andrew Spokes (1.0% of the portfolio) hold AGIO. These filings are published up to 45 days after each quarter ends, so positions may have changed since.

Cite this page

Funkfolio, “Agios Pharmaceuticals, Inc. (AGIO) stock: price, valuation and fundamentals”, data as of 17 November 2026. https://funkfolio.com/stock/AGIO

Underlying data: Yahoo Finance; company filings with the SEC.